BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Misses Revenue Estimates

Core Insights - BioXcel Therapeutics, Inc. reported a quarterly loss of $2.18 per share, which was worse than the Zacks Consensus Estimate of a loss of $1.54, representing an earnings surprise of -41.56% [1] - The company generated revenues of $0.1 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 34.67% and down from $0.21 million a year ago [2] - BioXcel shares have declined approximately 66.2% year-to-date, contrasting with the S&P 500's gain of 16.4% [3] Financial Performance - The company has surpassed consensus EPS estimates two times over the last four quarters [2] - The current consensus EPS estimate for the upcoming quarter is -$0.82 on revenues of $0.2 million, while for the current fiscal year, it is -$6.93 on revenues of $0.64 million [7] Market Outlook - The earnings outlook and estimate revisions will significantly influence the stock's immediate price movement [3][4] - The Zacks Rank for BioXcel is currently 3 (Hold), indicating expected performance in line with the market in the near future [6] - The Medical - Biomedical and Genetics industry is ranked in the top 34% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]